Scholar Rock Holding Corporation (SRRK) is a leading biopharmaceutical company that specializes in discove ring, designing, and developing new treatments targeting the transforming growth factor beta (TGFβ) superfamily of proteins. The company was founded in 2012 and has its headquarters in Cambridge, Massachusetts. It is well-known for its unique and proprietary platform that allows the specific targeting of latent TGFβ, a key component of numerous biological processes.
Scholar Rock’s platform is engineered to exploit the complexity of the TGFβ biology by specifically targeting and modulating its activation in a controlled way. This includes designing therapeutic antibodies that can precisely target these powerful proteins, which play key roles in a variety of conditions, including oncology, fibrosis, and immunology, among others.
An innovative forerunner in the field of biopharmaceuticals, Scholar Rock’s most advanced product candidate is SRK-015, an antibody against myostatin, which is in clinical development for the treatment of Spinal Muscular Atrophy (SMA). The company is committed to addressing unmet medical needs by delivering safer and more effective therapies to patients worldwide.
Scientific breakthroughs are at the core of Scholar Rock’s strategy. The company’s unique approach to understanding and targeting TGFβ activation empowers it to create innovative therapeutics that could revolutionize treatments for a broad range of serious diseases. One example is cancer, where TGFβ has been implicated both as a potential tumour promoter and suppressor, offering multiple avenues for new drug pipelines.
Scholar Rock has assembled a world-class team of researchers, clinical development experts, and industry leaders, creating a collaborative environment that nurtures scientific excellence and innovation. By combining a deep understanding of molecular biology with cutting-edge technology, the company is continually pushing the boundaries of what’s possible in drug discovery and development.
Since its inception, Scholar Rock has established numerous collaborations and partnerships with leading pharmaceutical and biotech companies. This indicates the wider industry’s recognition of the potential and value of Scholar Rock’s technology and therapeutic candidates. As its portfolio of therapeutic candidates grows, Scholar Rock continues to impact the lives of patients on a global scale.
Scholar Rock Holding Corp is listed on the NASDAQ Global Market under the ticker symbol "SRRK". Despite the typical challenges and risks tied to drug development, Scholar Rock remains steadfast in its mission of pioneering new frontiers in biomedical science, while keeping patient needs at the forefront of its endeavor.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Wedbush has added Scholar Rock Holding Corp. (SRRK) to its Best Ideas List, citing the company's strong position for commercial growth in the neuromuscular sector. The firm projects a $70 price target for SRRK, indicating a potential 44% upside from its previous closing price. This positive outlook suggests confidence in Scholar Rock's future performance.
Wedbush has assigned an "Outperform" rating to Scholar Rock (SRRK), citing its promising neuromuscular pipeline and recent product launch, ISEMBYLD, as key growth drivers. Despite the company's current unprofitability and high Price-to-Sales ratio of 30.4x, Wedbush believes recent stock weakness presents an entry point for investors. The article highlights SRRK's moderate financial strength but notes a low GF Score of 29/100 due to profitability and momentum challenges, alongside mixed insider sentiment.
Bank of America Corp DE has acquired a new stake of 972,257 shares in Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $53.47 million, representing about 0.8% of the company. Institutional investors now collectively own 91.08% of SRRK. Analyst sentiment remains positive, with a consensus "Buy" rating and an average price target of $66.00, while the company reported a quarterly EPS of -$0.84, meeting analyst expectations.
JP Morgan has reiterated an "Overweight" rating for Scholar Rock Holding Corp (SRRK), increasing its price target from $63.00 to $70.00. Despite this positive analyst outlook driven by its innovative pipeline in neuromuscular diseases, the company's GF Score™ is low at 29/100, indicating below-average performance in profitability and growth. Investors are cautioned due to the high price-to-sales ratio and mixed sentiment from institutional investors and insider selling activity.
Scholar Rock Holding Corporation (SRRK) received FDA approval for ISEMBYLD to treat spinal muscular atrophy (SMA) as an add-on to existing therapies. The drug demonstrated motor benefits in clinical trials, suggesting a complementary role to current treatments. However, its commercial success hinges on patient access, payer coverage, and managing the risk of fractures as a side effect.
The FDA has approved Scholar Rock's ISEMBYLD (apitegromab-mstn) for spinal muscular atrophy (SMA) in patients aged 2 and older, marking it as the first muscle-targeted therapy to improve motor function in individuals already on SMN2-targeted drugs. This approval, backed by positive Phase 3 SAPPHIRE study results, also earned Scholar Rock a Rare Pediatric Disease Priority Review Voucher. The company has begun the U.S. commercial launch of ISEMBYLD, which targets promyostatin and latent myostatin to inhibit myostatin activation.
Bank of New York Mellon Corp has acquired 365,218 shares of Scholar Rock Holding Corporation (NASDAQ:SRRK), valued at approximately $20.1 million, establishing a 0.30% stake in the company. Institutional investors now collectively own 91.08% of Scholar Rock, which has a consensus "Buy" rating and an average price target of $58.77 from Wall Street analysts. The clinical-stage biotech recently reported quarterly EPS of -$0.84, aligning with analyst expectations, and its stock opened near its 52-week high at $57.80.
Scholar Rock, a biopharmaceutical company, announced its participation in two upcoming investor conferences: the Cantor 2026 Global Healthcare Conference and the Citi 2026 BioPharma Back to School Conference. Management will engage in fireside chats at both events in New York, NY, on September 9 and September 10, 2026, respectively. Webcasts of these presentations will be available on the company's investor relations website.